346 related articles for article (PubMed ID: 27743957)
41. Breast Cancer Outcomes as Defined by the Estrogen Receptor, Progesterone Receptor, and Human Growth Factor Receptor-2 in a Multi-ethnic Asian Country.
Subramaniam S; Bhoo-Pathy N; Taib NA; Tan GH; See MH; Jamaris S; Ho GF; Looi LM; Yip CH
World J Surg; 2015 Oct; 39(10):2450-8. PubMed ID: 26138872
[TBL] [Abstract][Full Text] [Related]
42. Pattern of distant recurrence according to the molecular subtypes in Korean women with breast cancer.
Park HS; Kim S; Kim K; Yoo H; Chae BJ; Bae JS; Song BJ; Jung SS
World J Surg Oncol; 2012 Jan; 10():4. PubMed ID: 22226178
[TBL] [Abstract][Full Text] [Related]
43. [Clinical features and prognosis of patients with first-episode liver metastasis of different molecular subtypes of breast cancer].
Wu SY; Tan Y; Guan YS
Zhonghua Gan Zang Bing Za Zhi; 2016 Jun; 24(6):422-8. PubMed ID: 27465945
[TBL] [Abstract][Full Text] [Related]
44. A retrospective study of breast cancer subtypes: the risk of relapse and the relations with treatments.
Wang Y; Yin Q; Yu Q; Zhang J; Liu Z; Wang S; Lv S; Niu Y
Breast Cancer Res Treat; 2011 Nov; 130(2):489-98. PubMed ID: 21837481
[TBL] [Abstract][Full Text] [Related]
45. Identification of a Low-Risk Luminal A Breast Cancer Cohort That May Not Benefit From Breast Radiotherapy.
Liu FF; Shi W; Done SJ; Miller N; Pintilie M; Voduc D; Nielsen TO; Nofech-Mozes S; Chang MC; Whelan TJ; Weir LM; Olivotto IA; McCready DR; Fyles AW
J Clin Oncol; 2015 Jun; 33(18):2035-40. PubMed ID: 25964246
[TBL] [Abstract][Full Text] [Related]
46. Predictors of local recurrence following accelerated partial breast irradiation: a pooled analysis.
Shah C; Wilkinson JB; Lyden M; Beitsch P; Vicini FA
Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):e825-30. PubMed ID: 22330996
[TBL] [Abstract][Full Text] [Related]
47. Is conservative surgery a good option for patients with "triple negative" breast cancer?
Martinez-Ramos D; Escrig-Sos J; Torrella-Ramos A; Alcalde-Sanchez M; Salvador-Sanchis JL
Breast; 2012 Jun; 21(3):401-5. PubMed ID: 22579462
[TBL] [Abstract][Full Text] [Related]
48. Chemotherapy response and survival of inflammatory breast cancer by hormone receptor- and HER2-defined molecular subtypes approximation: an analysis from the National Cancer Database.
Liu J; Chen K; Jiang W; Mao K; Li S; Kim MJ; Liu Q; Jacobs LK
J Cancer Res Clin Oncol; 2017 Jan; 143(1):161-168. PubMed ID: 27704268
[TBL] [Abstract][Full Text] [Related]
49. Outcome in breast molecular subtypes according to nodal status and surgical procedures.
Mazouni C; Rimareix F; Mathieu MC; Uzan C; Bourgier C; André F; Delaloge S; Garbay JR
Am J Surg; 2013 Jun; 205(6):662-7. PubMed ID: 23312273
[TBL] [Abstract][Full Text] [Related]
50. The Effect of Molecular Subtype and Residual Disease on Locoregional Recurrence in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy and Postmastectomy Radiation.
Yang TJ; Morrow M; Modi S; Zhang Z; Krause K; Siu C; McCormick B; Powell SN; Ho AY
Ann Surg Oncol; 2015 Dec; 22 Suppl 3(Suppl 3):S495-501. PubMed ID: 26130454
[TBL] [Abstract][Full Text] [Related]
51. Basal vs. luminal A breast cancer subtypes: a matched case-control study using estrogen receptor, progesterone receptor, and HER-2 as surrogate markers.
Ibrahim E; Al-Gahmi AM; Zeenelin AA; Zekri JM; Elkhodary TR; Gaballa HE; Fawzy EE; El sayed ME; Alzahrani MS
Med Oncol; 2009; 26(3):372-8. PubMed ID: 19034706
[TBL] [Abstract][Full Text] [Related]
52. Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in five National Surgical Adjuvant Breast and Bowel Project node-positive adjuvant breast cancer trials.
Wapnir IL; Anderson SJ; Mamounas EP; Geyer CE; Jeong JH; Tan-Chiu E; Fisher B; Wolmark N
J Clin Oncol; 2006 May; 24(13):2028-37. PubMed ID: 16648502
[TBL] [Abstract][Full Text] [Related]
53. Breast Cancer Survival Analysis Based on Immunohistochemistry Subtypes (ER/PR/HER2): a Retrospective Cohort Study.
Poorolajal J; Nafissi N; Akbari ME; Mahjub H; Esmailnasab N; Babaee E
Arch Iran Med; 2016 Oct; 19(10):680-686. PubMed ID: 27743431
[TBL] [Abstract][Full Text] [Related]
54. Anthropometric factors and risk of molecular breast cancer subtypes among postmenopausal Norwegian women.
Horn J; Alsaker MD; Opdahl S; Engstrøm MJ; Tretli S; Haugen OA; Bofin AM; Vatten LJ; Asvold BO
Int J Cancer; 2014 Dec; 135(11):2678-86. PubMed ID: 24752603
[TBL] [Abstract][Full Text] [Related]
55. Reproductive factors and subtypes of breast cancer defined by estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2: a register-based study from Korea.
Lee JS; Oh M; ;
Clin Breast Cancer; 2014 Dec; 14(6):426-34. PubMed ID: 25034438
[TBL] [Abstract][Full Text] [Related]
56. Defining breast cancer prognosis based on molecular phenotypes: results from a large cohort study.
Dawood S; Hu R; Homes MD; Collins LC; Schnitt SJ; Connolly J; Colditz GA; Tamimi RM
Breast Cancer Res Treat; 2011 Feb; 126(1):185-92. PubMed ID: 20711652
[TBL] [Abstract][Full Text] [Related]
57. Clinical Characteristics and Prognosis of Pregnancy-Associated Breast Cancer: Poor Survival of Luminal B Subtype.
Bae SY; Jung SP; Jung ES; Park SM; Lee SK; Yu JH; Lee JE; Kim SW; Nam SJ
Oncology; 2018; 95(3):163-169. PubMed ID: 29913459
[TBL] [Abstract][Full Text] [Related]
58. Prognosis in women with small (T1mic,T1a,T1b) node-negative operable breast cancer by immunohistochemically selected subtypes.
Cancello G; Maisonneuve P; Rotmensz N; Viale G; Mastropasqua MG; Pruneri G; Montagna E; Dellapasqua S; Iorfida M; Cardillo A; Veronesi P; Luini A; Intra M; Gentilini O; Scarano E; Goldhirsch A; Colleoni M
Breast Cancer Res Treat; 2011 Jun; 127(3):713-20. PubMed ID: 21452022
[TBL] [Abstract][Full Text] [Related]
59. Different prognostic significance of Ki-67 change between pre- and post-neoadjuvant chemotherapy in various subtypes of breast cancer.
Matsubara N; Mukai H; Fujii S; Wada N
Breast Cancer Res Treat; 2013 Jan; 137(1):203-12. PubMed ID: 23184081
[TBL] [Abstract][Full Text] [Related]
60. Prognostic Impact of Time to Ipsilateral Breast Tumor Recurrence after Breast Conserving Surgery.
Gosset M; Hamy AS; Mallon P; Delomenie M; Mouttet D; Pierga JY; Lae M; Fourquet A; Rouzier R; Reyal F; Feron JG
PLoS One; 2016; 11(8):e0159888. PubMed ID: 27494111
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]